![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 35, 24445-24448, August 27, 1999
§,
,
,
,
§,
,
, and
**
From the
Departament de Biologia Cel.lular i Anatomia
Patològica, Institut d'Investigacions Biomèdiques August
Pi i Sunyer (IDIBAPS), Facultat de Medicina, Universitat de
Barcelona, 08036 Barcelona, Spain, the ¶ Department of
Pathology, Brigham and Women's Hospital and Harvard Medical School,
Boston, Massachusetts 02115, and the
Departamento de
Bioquímica y Biología Molecular, Universidad de
Valencia, E-46100 Burjassot, Valencia, Spain
| |
ABSTRACT |
|---|
|
|
|---|
p21Cip1, first described as an
inhibitor of cyclin-dependent kinases, has recently been
shown to have a function in the formation of cyclin D-Cdk4 complexes
and in their nuclear translocation. The dual behavior of
p21Cip1 may be due to its association with other proteins.
Different evidence presented here indicate an in vitro and
in vivo interaction of p21Cip1 with calmodulin:
1) purified p21Cip1 is able to bind to calmodulin-Sepharose
in a Ca2+-dependent manner, and this binding is
inhibited by the calmodulin-binding domain of
calmodulin-dependent kinase II; 2) both molecules
coimmunoprecipitate when extracted from cellular lysates; and 3)
colocalization of calmodulin and p21Cip1 can be detected
in vivo by electron microscopy immunogold analysis. The
carboxyl-terminal domain of p21Cip1 is responsible for the
calmodulin interaction, since p21145-164 peptide is also
able to bind calmodulin and to compete with full-length p21Cip1 for the calmodulin binding. Because treatment of
cells with anti-calmodulin drugs decreases the nuclear accumulation of
p21Cip1, we hypothesize that calmodulin interaction with
p21Cip1 is important for p21Cip1, and in
consequence for cyclin D-Cdk4, translocation into the cell nucleus.
In mammalian cells progression through the cell cycle is
regulated by a family of serine/threonine protein kinases called cyclin-dependent kinases
(Cdks)1 (1-4). Among these
kinases, cyclin D-Cdk4 is known to have an important role in
G1 progression. Cyclin D-Cdk4 participates in the
phosphorylation of the pRb family of proteins allowing expression of S
phase genes and thus progression to S phase (4-9). Cyclin D1-Cdk4
activity is regulated at different levels (1, 10): synthesis and
degradation of the cyclin, assembly of the complex, phosphorylation
(11, 12), binding of Cdk inhibitors (13), intracellular localization
(14, 15), and most probably association with other proteins not
characterized (16). Two of the Cdk inhibitors, p21Cip1 and
p27Kip1, have an important but controversial role in cyclin
D-Cdk4 regulation. Both proteins were first described as inhibitors of
cyclin D-Cdk4, cyclin E-Cdk2, and cyclin A-Cdk2. But recently, using
knockout cell lines for each one of them and double knockout, a role
for p21Cip1 and p27Kip1 in cyclin D-Cdk4
assembly and nuclear translocation has been proposed (17, 18).
Activation of cyclin D-Cdk4 occurs in response to extracellular signals
that, using different receptors and transduction pathways, end in
transcription and stabilization of cyclin D (19-22), assembly of the
complex (23), and its translocation to the nucleus (14) where the
activating kinase and the major substrates are found. CaM is a
Ca2+-binding protein and acts as transducer of the
intracellular Ca2+ signal. When bound to Ca2+,
CaM is able to bind to other proteins (CaM-binding proteins) and
regulate their activity (24-26). By binding to proteins, CaM is able
to regulate important cellular processes such as cell cycle (27-30).
In fact, during G1, CaM is essential to activate Cdk4 and
thus for the phosphorylation of pRb (14, 31). We have shown previously
that CaM regulates nuclear translocation of Cdk4 and cyclin D1 (14).
This regulation may be mediated by a CaM-binding protein present in the
complex, as suggested by the fact that Cdk4 and cyclin D1 from cellular
lysates both bind in a Ca2+-dependent manner to
CaM-Sepharose. We show here that bacterially expressed and purified
p21Cip1, but not p27Kip1, is able to bind
specifically to CaM and that CaM is essential for the accumulation of
p21Cip1 in the nuclei of proliferating cells.
Cell Cultures--
NRK cells were made quiescent by growing to
confluence in Dulbecco's minimum essential medium supplemented with
5% FCS and then kept for 3 days in the same medium but with only 0.5%
FCS. To allow reentry to the cell cycle, quiescent cells were
trypsinized and subcultured at a lower density in fresh medium
supplemented with 5% FCS. Namalwa cells were obtained from American
Type Culture Collection and cultured at 1 × 106
cells/ml in RPMI 1640 supplemented with 10% FCS.
Immunoprecipitation--
Immunoprecipitations were performed as
described elsewhere (32). Cells (5-10 × 107) were
lysed in 1 ml of buffer A (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% Nonidet P-40, 50 mM NaF, 0.1 mM Na3VO4, 1 mM
phenylmethylsulfonyl fluoride, and 10 µg/ml leupeptin). 3-5 mg of
protein from the lysates was incubated with 5 µg of polyclonal
anti-p21Cip1 (sc-397, Santa Cruz), 5 µg of monoclonal
anti-p21Cip1 (0P64, Calbiochem), or 5 µg of monoclonal
anti-CaM for 2 h at 4 °C. As a control, an equal amount of a
monoclonal nonrelated antibody or 1 µl of normal rabbit serum was
used. Protein immunocomplexes were then incubated with 40 µl of
protein A-Sepharose (for the polyclonal antibodies) or protein
G-Sepharose (for the monoclonal antibodies) for 1 h at 4 °C,
collected by centrifugation, washed three times in buffer A, and
solubilized in Laemmli sample buffer. Immunoprecipitated proteins were
then analyzed by electrophoresis and Western blotting. A cell lysate
was always loaded in the same gel as a control for the mobility of each protein.
Pull-downs with Purified Proteins--
All recombinant proteins
were obtained as GST fusion proteins: p27Kip1-GST was
obtained by digesting pET21a-p27 (gift of Dr. Massagué, Memorial
Sloan-Kettering Cancer Center, New York) with
NdeI-XboI and ligating into pGEX-KG (33); cyclin
D1-GST was obtained by digesting pET3d-cyclin D1 (34) with
NcoI-HindIII and ligating into pGEX-KG;
p21Cip1-GST was obtained by polymerase chain reaction
amplification of pBS-hp21 (gift of Dr. Massagué, Memorial
Sloan-Kettering Cancer Center, New York) and cloning into pGEX-KG in
NdeI-XboI sites; Cdk4-GST was obtained by
polymerase chain reaction amplification of a B-cell cDNA library
using a forward initial primer and a reverse terminal primer and
cloning into pGEX-KG in BamHI-HindIII sites. GST
fusion proteins were expressed in BL21 pLysE Escherichia coli strain and purified by gluthatione-Sepharose chromatography. CaM was purified from bovine brain, as described elsewhere (35). CaM
and p21145-164 peptide were bound to BrCN-activated
Sepharose 4B, as indicated by the manufacturer. For CaM-Sepharose
pull-downs, 1 µg of purified protein was incubated for 1 h at
4 °C with 20 µl of CaM-Sepharose (1:1 v/v) or Sepharose alone in a
buffer B (50 mM Tris-HCl, pH 7.4, 150 mM NaCl,
1% Triton X-100) containing either 1 mM EGTA or 0.1 mM CaCl2. After centrifugation, unbound
proteins were collected and bound proteins washed three times with
buffer B and eluted directly with SDS-polyacrylamide gel
electrophoresis Laemmli loading buffer, electrophoresed, and analyzed
by Coomassie Blue staining or Western blotting. For peptide competition
experiments, CaM-Sepharose was preincubated with 2 nmol of the peptides
in 200 µl of buffer B (containing only 50 mM NaCl) for
1 h at 4 °C. To determine binding of CaM to
p21145-164 peptide, 1 µg of purified CaM was incubated
for 1 h at 4 °C with 20 µl of
p21145-164-Sepharose (1:1 v/v) or Sepharose alone in
buffer B (containing 400 mM NaCl) containing either 1 mM EGTA or 0.1 mM CaCl2. After centrifugation, unbound protein was collected and bound protein washed
three times with buffer B (last wash with 100 mM NaCl) and
eluted directly with SDS-polyacrylamide gel electrophoresis Laemmli
loading buffer, electrophoresed, and analyzed by Coomassie Blue staining.
Gel Electrophoresis and Immunoblotting--
Proteins were
electrophoresed in SDS-polyacrylamide gels essentially as described
(38). After electrophoresis the proteins were either stained with
Coomassie Blue or transferred to Immobilon-P strips for 2 h at 60 V. In the case of CaM analysis 2 mM EGTA was added in the
loading buffer, and in the stacking and resolving gel solutions,
transfer was for 1 h at 60 V, and Immobilon-P was then treated
with 0.2% glutaraldehyde in TBS (20 mM Tris-HCl, pH 7.5, 150 mM NaCl) for 45 min and washed twice in TBS. The sheets were preincubated in TBS containing 0.05% Tween 20 and 5% defatted milk powder for 1 h at room temperature and then incubated for 1 h at room temperature in TBS, 0.05% Tween 20, 1% BSA, and
0.5% defatted milk powder containing antibodies against: Cdk4
(sc-260-R, Santa Cruz, 0.5 µg/ml), cyclin D (06-450,
Upstate Biotechnology, Inc., 2 µg/ml), p21Cip1 (sc-397,
Santa Cruz, 2 µg/ml), and p27Kip1 (1:500 dilution; gift
from Dr. Massagué, Memorial Sloan-Kettering Cancer Center, New
York) polyclonal antibodies or CaM monoclonal antibody. After washing
in TBS, 0.05% Tween 20 (three times, 10 min each), the sheets were
incubated with peroxidase-coupled secondary antibody (1:1000 dilution)
(Bio-Rad) for 1 h at room temperature. After incubation, the
sheets were washed twice in TBS, 0.05% Tween 20 and once in TBS and
the reaction visualized by ECL (Amersham Pharmacia Biotech).
Electron Microscopy--
To study colocalization of
p21Cip1 and CaM, NRK cells were grown on transwell filters.
Small pieces of the filters were cryofixed by protection against a
copper block cooled by liquid nitrogen ( Immunocytochemistry--
For p21Cip1 staining, cells
grown in coverslips were fixed in 3% paraformaldehyde/PBS (140 mM NaCl, 5 mM Na2HPO4,
1.5 mM KH2PO4, pH 7.2) for 20 min
at room temperature and permeabilized with 0.2% Triton X-100 in PBS
for 10 min at room temperature. Cells were then incubated for 1 h
at 37 °C in a humidified atmosphere, with the specific polyclonal
antibody anti-p21Cip1 (sc-397, Santa Cruz, 20 µg/ml).
Coverslips were then washed three times (5 min each) in PBS and
incubated for 45 min at 37 °C with fluorescein-conjugated
anti-rabbit antibody (dilution 1:100, Sigma). After two washes in PBS,
coverslips were mounted on glass slides with Mowiol (Calbiochem) and
observed in a confocal microscope.
In Vitro Association of p21Cip1 with CaM--
We had
shown previously that Cdk4 and CycD1 from cellular lysates could bind
to CaM in a Ca2+-dependent manner. To determine
whether one of the known proteins of the Cdk4-CycD1 complex was able to
bind directly to CaM, we tested the binding of bacterially expressed
and purified Cdk4-GST, CycD1-GST, p27Kip1-GST and
p21Cip1-GST to CaM-Sepharose. Pull-down experiments were
performed as indicated in the methods and demonstrate that
p21Cip1-GST bound to CaM-Sepharose in the presence of
Ca2+ but not in its absence (Fig.
1). CycD1-GST and
p27Kip1-GST, however, were found only in the fraction not
bound to the column either in the presence or in the absence of
Ca2+, and a small amount of Cdk4-GST was bound to the
CaM-Sepharose in the presence of Ca2+. Preincubation of
CaM-Sepharose with 2 nM (total volume 200 µl) of the
CaM-binding domain of the CaMKII (CaMKII290-309 fragment)
inhibited the binding of p21Cip1-GST to CaM, indicating
that p21Cip1-GST association with CaM was specific (Fig.
2B).
To determine which domains of p21Cip1 could be involved in
CaM interaction, three different peptides of the p21Cip1
molecule (Fig. 2A) were synthesized and assayed for
competition in the p21Cip1 binding to CaM-Sepharose. As
shown in Fig. 2B, preincubation of CaM-Sepharose with 2 nmol
of the p21145-164 peptide (total volume 200 µl)
inhibited the binding of p21Cip1, while the other peptides
had no effect. To further test that this peptide was the CaM-binding
domain of p21Cip1, the peptide was covalently bound to
Sepharose and pull-down experiments with purified CaM performed in the
presence or absence of free Ca2+. As shown in Fig.
2C, CaM was able to bind to
p21145-164-Sepharose, and the binding was
Ca2+-dependent.
Coimmunoprecipitation of p21Cip1 and CaM--
The
association between p21Cip1 and CaM was also analyzed by
immunoprecipitation (Fig. 3). When
lysates from Namalva cells were immunoprecipitated with anti-CaM
monoclonal antibody, p21CIP1 was detected by Western
blotting in the immunoprecipitates. Equally, CaM was detected in the
immunoprecipitates using monoclonal anti-p21Cip1
antibodies. Interestingly, no CaM was found to coimmunoprecipitate with
p21Cip1 when the antibodies used were the polyclonal
anti-p21Cip1 directed against the carboxyl terminus of the
p21Cip1 molecule (data not shown).
Colocalization of p21Cip1 and CaM Analyzed by Electron
Microscopy--
To support the hypothesis that interaction of CaM with
p21Cip1 could have a physiological role, in vivo
colocalization was analyzed by double immunogold labeling. Cryofixation
of proliferative activated NRK cells was achieved by slam freezing and,
as indicated under "Experimental Procedures," samples were
incubated with anti-CaM monoclonal antibody and
anti-p21Cip1 polyclonal antibody and processed for electron
microscopy. As shown in Fig.
4A, aggregates of CaM and
p21Cip1 were detected in the nucleus and in the cytoplasm.
Colocalization of Cdk4 and cyclin D1 in the cell nucleus with CaM was
also observed in samples processed by PLT method (Fig.
4B).
Anti-CaM Drug Addition Inhibits Nuclear Accumulation of
p21Cip1--
To analyze whether, as for cyclin D1 and
Cdk4, CaM was essential for nuclear accumulation of
p21Cip1, the anti-CaM drug W13 (15 µg/ml), or the control
drug W12 (15 µg/ml), was added to NRK cells 5 h after
proliferative activation. After 2 h of incubation with the drugs,
p21Cip1 intracellular distribution was analyzed by
immunocytochemistry. As shown in Fig. 5,
W13 addition caused a decrease in the nuclear staining for
p21Cip1 compared with the control drug, in parallel with an
increase in the cytoplasmic staining. Similar results were obtained
with other anti-CaM drugs such as J8 (7 µg/ml), W7 (10 µg/ml), or
calmidazolium (5 µM) (data not shown).
Although association of p21Cip1 with Cdk4-cyclin D1
complexes has been described in a great variety of cells, its role in
the regulation of Cdk4 activity is still controversial. While an
inhibitory role was first proposed (38, 39), recently it has been shown that this association is necessary for Cdk4-cyclin D1 assembly and its
nuclear translocation (17, 18). The diverse functionality of this
protein may depend on the number of molecules bound to each Cdk4-cyclin
D complex or to the association with other regulatory proteins. We show
here that CaM binds to p21Cip1 and so may be one of the
molecules regulating its activity. Evidence for this is as follows: 1)
purified p21Cip1 is able to bind in vitro to
CaM; 2) both molecules coimmunoprecipitate when extracted from cell
lysates; and 3) colocalization of CaM and p21Cip1 can be
detected in vivo by electron microscopy immunogold analysis.
On the contrary, although Cdk4 and cyclin D1 coimmunoprecipitate (14)
and colocalize by electron microscopy with CaM, when purified, they do
not bind (cyclin D1) or bind very little (Cdk4) to CaM. This indicates
that their association with CaM depends on another protein.
Interestingly, p27Kip1, which has some structural
similarity to p21Cip1, is clearly not a CaM-binding
protein. This points to a different regulation of p21Cip1
and p27Kip1 functions.
Interaction domains of p21Cip1 with Cdks and cyclins reside
in the amino-terminal half of the molecule (Cyc 21-26; Cdk 49-71). These regions are precisely the ones well conserved between
p21Cip1 and p27Kip1. The second half of the
molecule contains diverse nuclear localization signal (NLS) motif
(139-142, 160-163, 140-162, 141-158), the PCNA binding site
(124-164), and a cyclin A inhibitory binding domain (Fig.
1C) (40-43). In order to analyze the possible binding
domain of p21Cip1 to CaM, three different peptides were
synthesized and assayed for their ability to compete for the binding to
CaM. Among the peptides analyzed, the one corresponding to amino acids
145-164 prevented the binding of p21Cip1 to CaM.
Furthermore CaM was able to bind to a p21145-164
peptide-Sepharose column in a Ca2+-dependent
manner. This peptide contains basic and hydrophobic residues that,
plotted in a helical wheel diagram, show an amphipathic distribution.
Thus, this region corresponds most probably to the CaM-binding domain
of p21Cip1. This sequence is not present in the
p27Kip1 molecule, in agreement with the results presented
which show that p27Kip1 does not bind to CaM.
As mentioned above, apart from the inhibitory role of
p21Cip1 in Cdk-cyclin complexes, it has also been shown
that p21Cip1 is important for the assembly of Cdk4-cyclin
D1 and for its translocation to the cell nucleus (17, 18, 44). La Baer
et al. (17) showed that cells transfected with a truncated
p21Cip1 containing the amino-terminal half of the molecule
were able to form complexes with Cdk4 and cyclin D1, but these were not found in the cell nucleus. This suggested that p21Cip1
provides the nuclear localization signal for the nuclear import of the
complex. Interestingly, in p21 We have shown previously that inhibition of HSP90, which is a
CaM-binding protein that is associated with Cdk4, also inhibits nuclear
translocation of Cdk4 and cyclin D1 (14). CaM may be essential in two
steps leading to the nuclear translocation of Cdk4-cyclin D1 complexes:
first, through the action of HSP90 allowing a proper Cdk4 folding (45,
46) and binding to cyclin D1 and p21previously, and second, binding to
p21Cip1, so allowing its import to the nucleus.
Alternatively, the binding of CaM to p21Cip1 may regulate
another function of p21Cip1, which is not related to the
nuclear import of the complexes. The fact that the CaM-binding domain
of p21Cip1 is located inside the PCNA-binding domain
suggests that CaM may modulate the binding of p21Cip1 to
PCNA and thus its ability to inhibit DNA replication.
Although further studies are necessary to elucidate the role of CaM
binding to p21Cip1, the new findings presented here,
showing the in vitro interaction, the coimmunoprecipitation,
and the in vivo colocalization of CaM and
p21Cip1, open up the possibility of the regulation of
p21Cip1 functions in response to a Ca2+ signal
and in a different way from p27Kip1.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
196 °C) using a Cryoblock
(Leica) according to description (36). Freeze-substitution was
performed in a homemade cryosystem (37), using acetone containing 0.5%
of uranyl acetate, for 3 days at
90 °C. At day 4 the temperature
was slowly increased, 5 °C/h, to reach
50 °C. At this
temperature the samples were rinsed in acetone and were infiltrated and
embedded in Lowicryl HM20 as follows: 50% Lowicryl in acetone for
4 h, 75% Lowicryl in acetone overnight, 100% Lowicryl overnight
and 100% fresh resin for 4 h. After infiltration the resin blocks
were made and polymerized with UV lamps. Ultra-thin sections were
picked up on Formvar-coated gold grids in order to carry out the
immunocytochemical labeling. To study colocalization Cdk4 or cyclin D1
with CaM-pelleted cells were fixed in 3% paraformaldehyde and 0.1%
glutaraldehyde and 0.1 M phosphate buffer for 1 h at
room temperature, dehydrated according to the PLT technique
(progressive lowering temperature) and embedded in Lowicryl K4M.
Ultra-thin sections were mounted in Formvar-carbon-coated gold grids
and processed for immunocytochemical labeling as follows. After two
10-min washes with PBS (140 mM NaCl, 5 mM
Na2HPO4, 1.5 mM
KH2PO4, pH 7.2), grids were incubated for 5 min
with blocking solution (0.02 M glycine, 0.1% Tween 20, 0.1% BSA in PBS) and then incubated for 1 h at room temperature in the same solution containing either anti-Cdk4, anti-CycD1, or
anti-p21Cip1 polyclonal antibodies (1:50 dilution) together
with anti-CaM monoclonal antibody (1:500 dilution). After washing,
grids were incubated 1 h at room temperature with the same
solution but containing gold-coupled secondary antibodies (1:35,
British BioCell). Following that grids were sequentially washed with
0.1% BSA in PBS (10 min), PBS (5 min), and distilled water (30 min).
Finally samples were contrasted with 2% acetate uranyl in water during
30 min (samples processed by conventional PLT) or 5 min (samples
processed by slam freezing method).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (42K):
[in a new window]
Fig. 1.
p21Cip1 binding to
CaM-Sepharose. Bacterially expressed and purified GST-fused
p21Cip1, p27Kip1, cyclin D1 (CycD1), or Cdk4 (1 µg of each) were incubated with CaM-Sepharose (CaM-Seph)
or Sepharose alone (Seph), in the presence of either
Ca2+ or EGTA. Unbound proteins were collected, and after
extensive washing bound proteins were eluted with SDS containing buffer
as indicated under "Experimental Procedures." Bound and not bound
proteins were electrophoresed and stained with Coomassie Blue.

View larger version (21K):
[in a new window]
Fig. 2.
Analysis of the CaM-binding domain of
p21Cip1. A, scheme of the different known
binding and functional domains of p21Cip1 and sequence of
the different peptides analyzed for the ability to bind to CaM. Cyc,
cyclin-binding domain; cdk, Cdk-binding domain; PCNA,
PCNA-binding domain; NLS, putative nuclear localization
signals. B, competition assay with the three
p21Cip1 peptides and with the CaM-binding domain of
CaM-dependent kinase II
(CaMKII290-309). CaM-Sepharose was preincubated
with the different peptides in the presence of Ca2+, as
indicated under "Experimental Procedures," and then 1 µg of
p21Cip1 was added and incubated for 1 h in the same
buffer. The resin was washed and the amount of bound
p21Cip1 analyzed by Western blotting. A control was done in
the presence of EGTA in the buffer and no peptide added. C,
CaM binding to p21145-164 peptide. p21145-164
peptide was covalently bound to Sepharose 4B and CaM was incubated with
this resin in the presence of either Ca2+ or EGTA as
indicated under "Experimental Procedures." Unbound CaM was
collected and, after extensive washing, bound CaM was eluted with an
SDS-containing buffer. CaM present in both fractions was analyzed by
Coomassie Blue staining. A control of CaM binding to Sepharose 4B alone
in the presence of Ca2+ (Seph) was also
performed. Purified CaM was also loaded in the same gel
(CaM).
![]()
View larger version (10K):
[in a new window]
Fig. 3.
Coimmunoprecipitation of p21Cip1
and CaM. Namalwa cells were lysed and immunoprecipitated with
either anti-p21Cip1 monoclonal antibody, anti-CaM
monoclonal antibody, or a monoclonal nonrelated antibody
(Mab). After washing, immunoprecipitated proteins were
eluted with SDS-containing buffer and the presence of
coimmunoprecipitated CaM or p21Cip1 analyzed by Western
blotting.

View larger version (157K):
[in a new window]
Fig. 4.
Colocalization of p21Cip1,
Cdk4, and cyclin D1 by electron microscopy.
A, NRK cells were processed by the slam freezing technique,
and immunodetection of CaM (5-nm gold particles) and
p21Cip1 (10-nm gold particles) performed as indicated under
"Experimental Procedures." Electronmicrographs a,
b, and c are examples of CaM and
p21Cip1 aggregates found in the nucleus (nu).
Electronmicrograph d corresponds to a cytoplasmic
(cy) aggregate near the nuclear envelope. B, NRK
cells were processed by conventional PLT technique and immunodetection
of CaM (5-nm gold particles), Cdk4, or cyclin D1 (10-nm gold particles)
performed as indicated under "Experimental Procedures." Micrograph
a shows nuclear aggregates of CaM and Cdk4. Micrograph
b shows nuclear aggregates of CaM and cyclin D1. In all
electromicrographs, bars correspond to 0.1 µm.

View larger version (32K):
[in a new window]
Fig. 5.
W13 addition inhibits nuclear accumulation of
p21Cip1. Quiescent NRK cells were activated to
proliferate, and 5 h after activation W12 or W13 (15 µg/ml) was
added to the medium. 2 h latter cells were fixed and
p21Cip1 immuodetection performed as indicated under
"Experimental Procedures."
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/p21
cells
Cdk4 and cyclin D1 were found in the nucleus, most probably because
p27Kip1 was then able to bind to Cdk4 and cyclin D1 and
provide the NLS signal. In double p21Cip1 and
p27Kip1 knockouts the number of cells with nuclear Cdk4 and
cyclin D1 was greatly reduced (18). Our finding that functional
inhibition of CaM during G1 inhibited nuclear accumulation
of p21Cip1 opens the possibility that binding of CaM to
p21Cip1 exposes an NLS of p21Cip1, so allowing
its nuclear translocation. Previous results showing that CaM inhibition
was also blocking nuclear accumulation of Cdk4-cyclin D1(14), lead us
to suggest that CaM, through the binding to p21Cip1,
activates the translocation of Cdk4-cyclin D1-p21Cip1
complexes to the cell nucleus in response to a Ca2+ signal.
However, this possibility remains to be demonstrated.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. Joan Massagué (New York) for the gift of anti-p27Kip1 antibodies and pBS-hp21Cip1 and pET21a-p27 plasmids. We also thank S. Porter (Washington University Medical Center, St. Louis, MO) for preparing anti-CaM antibody. We are also grateful to Anna Bosch (Serveis Científico-Tècnics, Universitat de Barcelona, Campus Medicina, Institut d'Investigacions Biomèdiques August Pi i Sunyer) for the technical assistance in confocal microscopy and to Carmen López, David Bellido, and Núria Cortadellas (Serveis Científico-Tècnics, Universitat de Barcelona) for technical assistance in electron microscopy.
| |
FOOTNOTES |
|---|
* This work was supported by Commisión Interministerial de Ciencia y Tecnología (Spain) Grants SAF97-0069 and SAF98-0014 and National Institutes of Health Grant CA75205.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Recipient of a predoctoral fellowship from the University of Barcelona.
** To whom correspondence should be addressed: Dept. Biologia Cel.lular, Fac. Medicina, Universitat de Barcelona, C/Casanova 143, 08036 Barcelona, Spain. Tel.:/Fax: 3493-4021907; E-mail: agell@medicina.ub. es.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: Cdk, cyclin-dependent kinase; CaM, calmodulin; NRK, normal Rat kidney; FCS, fetal calf serum; BSA, bovine serum albumin; PBS, phosphate-buffered saline; NLS, nuclear location sequence; W12, N-(4-aminobutyl)-2-naphthalenesulfonamide; W13, N-(4-aminobutyl)-5-chloro-2- naphthalenesulfonamide; W7, N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide; J8, N-(8-aminooctyl)-5-iodo-1-naphthalenesulfonamide; GST, glutathione S-transferase; PLT, progressive lowering temperature; PCNA, proliferating cell nuclear antigen.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Morgan, D. O. (1997) Annu. Rev. Cell Dev. Biol. 13, 261-291 [CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Norbury, C., and Nurse, P. (1992) Annu. Rev. Biochem. 61, 441-470[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Reed, S. I. (1992) Annu. Rev. Cell Biol. 8, 529-561[CrossRef] |
| 4. | Sherr, C. J. (1994) Cell 79, 551-555[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Resnitzky, D., and Reed, S. (1995) Mol. Cell. Biol. 15, 3463-3469[Abstract] |
| 6. |
Dong, F.,
Cress, W. D., Jr.,
Agrawal, D.,
and Pledger, W. J.
(1998)
J. Biol. Chem.
273,
6190-6195 |
| 7. | Mittnacht, S. (1998) Curr. Opin. Genet. Dev. 8, 21-27[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | Lam, E., and La Thangue, N. (1994) Curr. Opin. Cell Biol. 6, 859-866[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Weinberg, R. A. (1995) Cell 81, 323-330[CrossRef][Medline] [Order article via Infotrieve] |
| 10. | Morgan, D. (1995) Nature 374, 131-134[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Jinno, S., Suto, K., Nagata, A., Igarashi, M., Kanaoka, Y., Nojima, H., and Okayama, H. (1994) EMBO J. 13, 1549-1556[Medline] [Order article via Infotrieve] |
| 12. |
Kato, J.,
Matsuoka, M.,
Strom, D. K.,
and Sherr, C. J.
(1994)
Mol. Cell. Biol.
14,
2713-2721 |
| 13. |
Sherr, C.,
and Roberts, J.
(1995)
Genes Dev.
9,
1149-1163 |
| 14. |
Taules, M.,
Rius, E.,
Talaya, D.,
Lopez, G. A.,
Bachs, O.,
and Agell, N.
(1998)
J. Biol. Chem.
273,
33279-33286 |
| 15. |
Depoortere, F.,
Van Keymeulen, A.,
Lukas, J.,
Costagliola, S.,
Bartkova, J.,
Dumont, J. E.,
Bartek, J.,
Roger, P. P.,
and Dremier, S.
(1998)
J. Cell Biol.
140,
1427-1439 |
| 16. | Mahony, D., Parry, D. A., and Lees, E. (1998) Oncogene 16, 603-611[CrossRef][Medline] [Order article via Infotrieve] |
| 17. |
La Baer, J.,
Garrett, M. D.,
Stevenson, L. F.,
Slingerland, J. M.,
Sandhu, Ch.,
Chou, H. S.,
Fattaey, A.,
and Harlow, E.
(1997)
Genes Dev.
11,
847-862 |
| 18. | Cheng, M., Olivier, P., Diehl, J. A., Fero, M., Roussel, M. F., Roberts, J. M., and Sherr, C. J. (1999) EMBO J. 18, 1571-1583[CrossRef][Medline] [Order article via Infotrieve] |
| 19. |
Albanese, C.,
Johnson, J.,
Watanabe, G.,
Eklund, N.,
Vu, D.,
Arnold, A.,
and Pestell, R. G.
(1995)
J. Biol. Chem.
270,
23589-23597 |
| 20. |
Lavoie, J. N.,
Lallemain, G.,
Brunet, A.,
Muller, R.,
and Pouyssegur, J.
(1996)
J. Biol. Chem.
271,
20608-20616 |
| 21. |
Diehl, J. A.,
Cheng, M. G.,
Roussel, M. F.,
and Sherr, C. J.
(1998)
Genes Dev.
12,
3499-3511 |
| 22. |
Diehl, J. A.,
Zindy, F.,
and Sherr, C. J.
(1997)
Genes Dev.
11,
957-972 |
| 23. |
Cheng, M.,
Sexl, V.,
Sherr, C. J.,
and Roussel, M. F.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
1091-1096 |
| 24. | Klee, C., and Vanaman, T. (1982) Adv. Protein Chem. 35, 213-321[Medline] [Order article via Infotrieve] |
| 25. | James, P., Vorherr, T., and Carafoli, E. (1995) Trends Biochem. Sci. 20, 38-42[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Bachs, O., Agell, N., and Carafoli, E. (1994) Cell Calcium 16, 289-296[CrossRef][Medline] [Order article via Infotrieve] |
| 27. | Lu, K. P., and Means, A. R. (1993) Endocr. Rev. 14, 40-57[CrossRef][Medline] [Order article via Infotrieve] |
| 28. | López-Girona, A., Bachs, O., and Agell, N. (1995) Biochem. Biophys. Res. Commun. 217, 566-574[CrossRef][Medline] [Order article via Infotrieve] |
| 29. | López-Girona, A., Bosch, M., Bachs, O., and Agell, N. (1995) Cell Calcium 18, 30-40[CrossRef][Medline] [Order article via Infotrieve] |
| 30. | López-Girona, A., Colomer, J., Pujol, M. J., Bachs, O., and Agell, N. (1992) Biochem. Biophys. Res. Commun. 184, 1517-1523[CrossRef][Medline] [Order article via Infotrieve] |
| 31. |
Takuwa, N.,
Zhou, W.,
Kumada, M.,
and Takuwa, T.
(1993)
J. Biol. Chem.
268,
138-145 |
| 32. | Harlow, E., and Lane, D. (1988) Antibodies: A Laboratory Manual , pp. 421-466, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY |
| 33. | Guan, K. L., and Dixon, J. E. (1991) Anal. Biochem. 192, 262-267[CrossRef][Medline] [Order article via Infotrieve] |
| 34. | Xiong, Y., Connolly, T., Futcher, B., and Beach, D. (1991) Cell 65, 691-699[CrossRef][Medline] [Order article via Infotrieve] |
| 35. |
Guerini, D.,
Krebs, J.,
and Carafoli, E.
(1984)
J. Biol. Chem.
259,
15172-15177 |
| 36. | Escaig, J. (1982) J. Microsc. 126, 221-229 |
| 37. | Quintana, C. (1994) Micron 25, 63-99 |
| 38. | Harper, J. W., Adami, G., Wei, N., Keyomarsi, K., and Elledge, S. J. (1993) Cell 75, 805-816[CrossRef][Medline] [Order article via Infotrieve] |
| 39. | Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. (1993) Nature 366, 701-704[CrossRef][Medline] [Order article via Infotrieve] |
| 40. | Lin, J., Reichner, C., Wu, X., and Levine, A. J. (1996) Mol. Cell. Biol. 16, 1793-1796 |
| 41. | Chen, J., Saha, P., Kornbluth, S., Dynlacht, B. D., and Dutta, A. (1996) Mol. Cell. Biol. 16, 4673-4682[Abstract] |
| 42. | Petersen, B. O., Lukas, J., Sorensen, C. S., Bartek, J., and Helin, K. (1999) EMBO J. 18, 396-410[CrossRef][Medline] [Order article via Infotrieve] |
| 43. | Russo, A. A., Jeffrey, P. D., Patten, A. K., Massagué, J., and Pavletich, N. P. (1996) Nature 382, 325-331[CrossRef][Medline] [Order article via Infotrieve] |
| 44. |
Cai, K.,
and Dynlacht, B. D.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
12254-12259 |
| 45. |
Stepanova, L.,
Leng, X.,
Parker, S. B.,
and Harper, J. W.
(1996)
Genes Dev.
10,
1491-1502 |
| 46. |
Dai, K.,
Kobayashi, R.,
and Beach, D.
(1996)
J. Biol. Chem.
271,
22030-22034 |
This article has been cited by other articles:
![]() |
J. Zhan, J. B. Easton, S. Huang, A. Mishra, L. Xiao, E. R. Lacy, R. W. Kriwacki, and P. J. Houghton Negative Regulation of ASK1 by p21Cip1 Involves a Small Domain That Includes Serine 98 That Is Phosphorylated by ASK1 In Vivo Mol. Cell. Biol., May 1, 2007; 27(9): 3530 - 3541. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Choi, A. Chiang, N. Taulier, R. Gros, A. Pirani, and M. Husain A Calmodulin-Binding Site on Cyclin E Mediates Ca2+-Sensitive G1/S Transitions in Vascular Smooth Muscle Cells Circ. Res., May 26, 2006; 98(10): 1273 - 1281. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Yu, J. Megyesi, R. L. Safirstein, and P. M. Price Identification of the functional domain of p21WAF1/CIP1 that protects cells from cisplatin cytotoxicity Am J Physiol Renal Physiol, September 1, 2005; 289(3): F514 - F520. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Rodriguez-Vilarrupla, M. Jaumot, N. Abella, N. Canela, S. Brun, C. Diaz, J. M. Estanyol, O. Bachs, and N. Agell Binding of Calmodulin to the Carboxy-Terminal Region of p21 Induces Nuclear Accumulation via Inhibition of Protein Kinase C-Mediated Phosphorylation of Ser153 Mol. Cell. Biol., August 15, 2005; 25(16): 7364 - 7374. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Tamori, Y. Yamanishi, S. Kawashima, M. Kanehisa, M. Enomoto, H. Tanaka, S. Kubo, S. Shiomi, and S. Nishiguchi Alteration of Gene Expression in Human Hepatocellular Carcinoma with Integrated Hepatitis B Virus DNA Clin. Cancer Res., August 15, 2005; 11(16): 5821 - 5826. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Sim, K. Rimmer, S. Kelly, L. M. Ludbrook, A. H. A. Clayton, and V. R. Harley Defective Calmodulin-Mediated Nuclear Transport of the Sex-Determining Region of the Y Chromosome (SRY) in XY Sex Reversal Mol. Endocrinol., July 1, 2005; 19(7): 1884 - 1892. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Khanna, M. Plummer, V. Nilakantan, and G. M. Pieper Recombinant p21 Protein Inhibits Lymphocyte Proliferation and Transcription Factors J. Immunol., June 15, 2005; 174(12): 7610 - 7617. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Cifuentes, J. M. Mataraza, B. A. Yoshida, M. Menon, D. B. Sacks, E. R. Barrack, and G. P.-V. Reddy Physical and functional interaction of androgen receptor with calmodulin in prostate cancer cells PNAS, January 13, 2004; 101(2): 464 - 469. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Kahl and A. R. Means Regulation of Cell Cycle Progression by Calcium/Calmodulin-Dependent Pathways Endocr. Rev., December 1, 2003; 24(6): 719 - 736. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Argentaro, H. Sim, S. Kelly, S. Preiss, A. Clayton, D. A. Jans, and V. R. Harley A SOX9 Defect of Calmodulin-dependent Nuclear Import in Campomelic Dysplasia/Autosomal Sex Reversal J. Biol. Chem., September 5, 2003; 278(36): 33839 - 33847. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. R. Harley, S. Layfield, C. L. Mitchell, J. K. Forwood, A. P. John, L. J. Briggs, S. G. McDowall, and D. A. Jans Defective importin {beta} recognition and nuclear import of the sex-determining factor SRY are associated with XY sex-reversing mutations PNAS, June 10, 2003; 100(12): 7045 - 7050. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Canela, A. Rodriguez-Vilarrupla, J. M. Estanyol, C. Diaz, M. J. Pujol, N. Agell, and O. Bachs The SET Protein Regulates G2/M Transition by Modulating Cyclin B-Cyclin-dependent Kinase 1 Activity J. Biol. Chem., January 3, 2003; 278(2): 1158 - 1164. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Li, D. Zhang, and K. Fujise Characterization of Fortilin, a Novel Antiapoptotic Protein J. Biol. Chem., December 7, 2001; 276(50): 47542 - 47549. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Villalonga, C. Lopez-Alcala, M. Bosch, A. Chiloeches, N. Rocamora, J. Gil, R. Marais, C. J. Marshall, O. Bachs, and N. Agell Calmodulin Binds to K-Ras, but Not to H- or N-Ras, and Modulates Its Downstream Signaling Mol. Cell. Biol., November 1, 2001; 21(21): 7345 - 7354. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Egea, C. Espinet, R. M. Soler, X. Dolcet, V. J. Yuste, M. Encinas, M. Iglesias, N. Rocamora, and J. X. Comella Neuronal survival induced by neurotrophins requires calmodulin J. Cell Biol., August 6, 2001; 154(3): 585 - 598. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. LANG, A. HARTNER, R. B. STERZEL, and H. O. SCHÖCKLMANN Requirement of Cyclin D1 in Mesangial Cell Mitogenesis J. Am. Soc. Nephrol., August 1, 2000; 11(8): 1398 - 1408. [Abstract] [Full Text] |
||||
![]() |
C. Yang, R. T. Watson, J. S. Elmendorf, D. B. Sacks, and J. E. Pessin Calmodulin Antagonists Inhibit Insulin-Stimulated GLUT4 (Glucose Transporter 4) Translocation by Preventing the Formation of Phosphatidylinositol 3,4,5-Trisphosphate in 3T3L1 Adipocytes Mol. Endocrinol., February 1, 2000; 14(2): 317 - 326. [Abstract] [Full Text] |
||||
![]() |
T. Ono, H. Kitaura, H. Ugai, T. Murata, K. K. Yokoyama, S. M. M. Iguchi-Ariga, and H. Ariga TOK-1, a Novel p21Cip1-binding Protein That Cooperatively Enhances p21-dependent Inhibitory Activity toward CDK2 Kinase J. Biol. Chem., September 29, 2000; 275(40): 31145 - 31154. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Li, J. L. Joyal, and D. B. Sacks Calmodulin Enhances the Stability of the Estrogen Receptor J. Biol. Chem., May 11, 2001; 276(20): 17354 - 17360. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. E. Harris, J. H. Albrecht, M. Nakanishi, and G. J. Darlington CCAAT/Enhancer-binding Protein-alpha Cooperates with p21 to Inhibit Cyclin-dependent Kinase-2 Activity and Induces Growth Arrest Independent of DNA Binding J. Biol. Chem., July 27, 2001; 276(31): 29200 - 29209. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||